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Alzheimer’s disease (AD) is characterized by neuronal and synaptic loss. One process
that could contribute to this loss is the intracellular caspase cleavage of the amyloid
precursor protein (APP) resulting in release of the toxic C-terminal 31-amino acid peptide
APP-C31 along with the production of APP1C31, full-length APP minus the C-terminal
31 amino acids. We previously found that a mutation in APP that prevents this caspase
cleavage ameliorated synaptic loss and cognitive impairment in a murine AD model.
Thus, inhibition of this cleavage is a reasonable target for new therapeutic development.
In order to identify small molecules that inhibit the generation of APP-C31, we first
used an APP1C31 cleavage site-specific antibody to develop an AlphaLISA to screen
several chemical compound libraries for the level of N-terminal fragment production.
This antibody was also used to develop an ELISA for validation studies. In both high
throughput screening (HTS) and validation testing, the ability of compounds to inhibit
simvastatin- (HTS) or cerivastatin- (validation studies) induced caspase cleavage at
the APP-D720 cleavage site was determined in Chinese hamster ovary (CHO) cells
stably transfected with wildtype (wt) human APP (CHO-7W). Several compounds,
as well as control pan-caspase inhibitor Q-VD-OPh, inhibited APP1C31 production
(measured fragment) and rescued cell death in a dose-dependent manner. The effective
compounds fell into several classes including SERCA inhibitors, inhibitors of Wnt
signaling, and calcium channel antagonists. Further studies are underway to evaluate
the efficacy of lead compounds – identified here using cells and tissues expressing wt
human APP – in mouse models of AD expressing mutated human APP, as well as to
identify additional compounds and determine the mechanisms by which they exert their
effects.
Keywords: AD – Alzheimer’s disease, APP – amyloid precursor protein, APP-C31 –C-terminal 31 amino acid
fragment of APP, APP1C31 – N-terminal APP fragment minus C-terminal 31 amino acids (alphabetical), statins
INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by cognitive
and functional decline. Pathologically, it is characterized by two types of lesions in the
brain: extracellular senile plaques consisting primarily of amyloid precursor protein (APP)-
derived amyloid-β (Aβ) peptide (Ikeda et al., 1987; Hardy and Allsop, 1991) and intracellular
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neurofibrillary tangles consisting largely of hyper-
phosphorylated microtubule-associated tau protein (Goedert,
1993; Dickson, 1997). Synapse loss and neuronal cell death
represent the basis for cognitive impairment in AD (Scheff et al.,
1996; Lacor et al., 2007), and the C-terminal caspase cleavage of
APP resulting in release of a 31 amino acid C-terminal fragment
(APP-C31) has been shown to be a likely contributor to neuronal
death in AD (Lu et al., 2000; Banwait et al., 2008).
As shown in Figure 1, APP may be cleaved by an α-secretase
(putatively ADAM10) to generate soluble APPα (sAPPα) and
the alpha C-terminal fragment (αCTF) which support synaptic
connections and neuronal survival. Alternatively, APP may
be cleaved by β-secretase BACE1 resulting in sAPPβ and
βCTF, the latter of which can then be further cleaved by
the γ -secretase complex to give Aβ of a variety of lengths
and the APP intracellular domain (AICD). AICD (or larger
APP species) can undergo caspase cleavage giving rise to,
for example, Jcasp and APP-C31. Full-length APP is also
subject to caspase cleavage, resulting in generation of APP1C31
(measured here) and APP-C31. APP1C31 has been found in
higher levels in the brains of patients with AD as compared
to controls, as determined by immunoblotting (Lu et al.,
2000) and immunohistochemistry (Banwait et al., 2008) using
a caspase cleavage-site specific antibody. This C-terminal APP
proteolytic cleavage is markedly increased in early stages of
AD as related to Braak staging (Braak and Braak, 1997);
increased staining is seen in the hippocampal region and around
some plaque and tangle-like structures as well as in peri-
and intra- neuronal regions of AD brains, whereas minimal
reactivity is seen in age-matched control patients (Banwait et al.,
2008).
The original finding that caspase cleavage of APP and
generation of APP-C31 was toxic and could lead to apoptosis
in vitro was presented in Lu et al. (2000), and additional
studies showed production of APP-C31 could be mediated by Aβ
interaction with full-length APP, resulting in dimerization and
caspase cleavage (Shaked et al., 2006). Studies by McPhie et al.
(2001) demonstrated that overexpression of the APP-C31 peptide
in primary cortical neurons via an HSV vector significantly
increased apoptosis over controls, that the generation of APP-
C31 occurred in the absence of γ-secretase cleavage, and that
this toxic pathway was enhanced in the presence of familial
Alzheimer’s disease (FAD) β-site mutations.
In earlier studies to determine the impact of inhibition
of APP-C31 production in vivo, we created transgenic mice
similar to the well-characterized J9 and J20 PDAPP models
of AD described elsewhere (Hsia et al., 1999; Mucke et al.,
2000), but with a D664A mutation that prevented caspase
cleavage and APP-C31 generation (Galvan et al., 2006). J9
and J20 mice express human APP (hAPP) containing the
Swedish and Indiana FAD mutations under the control of
the platelet-derived growth factor (PDGF) promoter, with
expression being higher in J20. The Swedish mutation increases
BACE cleavage of APP and the Indiana mutation increases
Aβ1-42 production over other Aβ species. In our B21 and
B254 lines with the D664A mutation having expression levels
similar to the J9 and J20 lines, respectively, we found that
much of the AD phenotype was ameliorated including changes
in long-term potentiation (LTP) and loss of hippocampal
volume (Galvan et al., 2006). In another study (Harris et al.,
2010), comparing J20 mice to B254 mice with the D664A
mutation, the B254 mice did not show the dramatic behavioral
FIGURE 1 | Amyloid precursor protein (APP) proteolytic processing. Full-length amyloid precursor protein (FL APP) may be cleaved by α-secretase (putatively
ADAM10) to produce trophic fragment soluble APPalpha (sAPPα) and the alpha C-terminal fragment (α-CTF). Alternatively, FL APP may be cleaved by β-secretase
(BACE1), generating sAPPβ and β-CTF; the latter is cleaved by γ -secretase, producing amyloid-beta (Aβ) and the APP intracellular domain (AICD). Should AICD
undergo caspase cleavage, Jcasp and C31 are generated. FL APP can also undergo caspase cleavage, producing APP1C31 and the C31 fragment. APP131 is
the fragment that is detected by the assays described here. The antibody generated by Enzo was raised against the C-terminal amino acids comprising the “neo”
epitope (circled in red) of APP131 after caspase cleavage of APP.
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improvements seen in the original study, however in that
study B254 mice were found to have significantly higher
Aβ production and plaque load compared to the J20 mice,
therefore it was stated by the authors of this study that the
D664A mutation may have had a protective effect after all,
making hAPP-B254 mice relatively resistant against higher
levels of Aβ. Thus, induction of APP-C31 production may be
one way in which Aβ exerts its deleterious effects, and thus
inhibition of this cleavage could be a new target for AD drug
discovery.
In this work, we set out to identify small molecule inhibitors
of the APP-C31 generating cleavage pathway. Such an effort,
we posited, could lead to chemical-genetic tools that could
reveal mechanisms and pathways in APP-C31 production and
neurotoxicity. For our studies, we measured APP1C31 rather
than APP-C31 levels as the latter peptide is short-lived and
difficult to detect. Our prior studies have shown the ability
of statins, particularly lipophilic statins such as simvastatin
and cerivastatin, to stimulate APP1C31 production (Descamps
et al., 2011). As a result, we utilized statins to stimulate
the intracellular caspase cleavage of APP at D720 (APP751
numbering) in vitro in CHO-7W cells stably overexpressing
hAPPwt so as to be able to more easily detect and then inhibit
this cleavage. The approach described herein, as well as the
target of screening – lowering of APP1C31 and resulting APP-
C31 – represents a new approach to therapeutic development
in AD that may alter the course of disease in its early
stages.
MATERIALS AND METHODS
Anti-APP1C31 Polyclonal Antibody and
Validation
In order to more accurately and sensitively quantify caspase-
cleaved APP in cell and tissue lysates, we partnered with Enzo
Life Sciences to develop both a cleavage site-specific (neo epitope)
polyclonal antibody that recognizes the C-terminus of APP1C31
resulting from the caspase cleavage and an ELISA (ENZ-ABS445-
0100, ADI-900-227, respectively). The immunizing antigen
comprised a short peptide sequence on the C-terminus of
APP1C31 (red circle, Figure 1).
The specificity of the antibody for the neo epitope,
rather than full length APP, was validated by immunoblot
(Figures 2A,B, Supplementary Figure S1A) and ELISA
(Supplementary Figure S1B). Human embryonic kidney (HEK
293T) cells were grown in high glucose DMEM with 10% heat-
inactivated fetal bovine serum and 1X antibiotic/antimycotic
and transfected with full-length pcDNA3-APP695, pcDNA3-
APP1C31, or empty pcDNA3 vector using Lipofectamine
2000 (Life Technologies). Two days later, RIPA buffer
lysates complemented with complete protease inhibitors
(PI, Roche) were prepared. Samples were run on 12% Bio-Rad
Criterion gels, transferred onto 0.2 µm PVDF membrane
and probed with the anti-APP1C31 antibody. Anti-rabbit
secondary antibody conjugated to HRP (horseradish peroxidase,
Amersham) was then incubated with the membrane, signal
was generated using chemiluminescence (Thermo) and film
FIGURE 2 | Anti-APP1C31 antibody and AlphaLISA. (A) The anti-APP1C31 antibody only detects APP1C31 in pcDNA3-APP1C31-transfected (lane 2) human
embryonic kidney (HEK 293T) cells, and not in cells transfected with full-length pcDNA3-APP695 (lane one) or empty vector (lane 3). (B) Similarly, the antibody
detects only APP1C31 in Chinese hamster ovary cells stably transfected with human APP751 (CHO-7W) when the cells are treated with caspase cleavage-inducing
staurosporine (Str) or simvastatin (SV) (both at 10 µM). There is some non-specific labeling of lower MW bands that is seen in both cell types. The AlphaLISA,
however, uses a second APP- specific antibody to limit detection to capase-cleaved APP only. (C) The caspase cleavage site of APP and its juxtaposition to the
plasma membrane is shown (yellow arrow). (D) APP1C31 is bound by both an anti-APP N-terminal specific antibody (bound to donor beads). (E) The anti-
APP1C31 antibody (bound to acceptor beads) to allow specific detection of APP1C31. Only when the donor and acceptor beads are in close proximity to each
other does excitation at 680 nm producing O2 result in emission from the acceptor bead at 580 nm that is detectable by the plate reader.
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exposed. In addition, samples were analyzed by APP1C31
ELISA.
Similarly, Chinese hamster ovary cells stably transfected
with human wildtype (wt) APP751 (CHO- 7W, a kind gift
from Dr. Edward Koo) were cultured in DMEM, 10% FBS,
1X antibiotic/antimycotic. They were treated with activated
simvastatin or staurosporine both at 10 µM for 24 h. RIPA lysates
were prepared using complete protease inhibitors (Roche).
For immunoprecipitation, approximately 300 µg cell lysate
supernatants were brought to 250 µL with cold RIPA+ PI buffer
in microfuge tubes. One µL of 6E10 APP antibody (Covance) was
added and the mixture was rotated overnight in a cold room. The
next day, 25 µL of protein A/G beads (Santa Cruz Biotech) were
added and the samples were rotated for 1.5 h in the cold room.
The beads were then centrifuged down and washed four times
with cold PBS. Forty µL 1x LDS sample buffer+DTT was added
to the pellets, which were heated to 70◦C for 10 min, vortexed and
centrifuged. Supernatants were loaded onto Nupage 4–12% Bis-
Tris gels (Life Technologies) for electrophoresis and were then
transferred to 0.2 µm PVDF membrane for immunoblotting with
the anti-APP1C31 antibody.
AlphaLISA to Detect APP1C31
A custom AlphaLISA (Perkin-Elmer) was developed to quantitate
APP1C31 in the CHO-7W screening studies described herein.
As shown in Figures 2C–E, biotinylated N-terminal APP
antibody AF1168 (R&D) is bound to streptavidin-conjugated
donor beads, and the Enzo anti-APP1C31 antibody is used
to coat acceptor beads. In the assay, 0.003 µL N-terminal
anti-APP antibody/µL and 0.002 µL acceptor-bead-bound anti-
APP1C31 antibody/µL are added to samples in 1X HiBlock
AlphaLISA buffer (Perkin-Elmer) on the assay plates. Plates are
sealed and pulse centrifuged at 1000 rpm after each addition
or mix step, shaken for 1 hr, and then incubated an additional
hour without shaking in the dark. Streptavidin donor beads
(PerkinElmer) are then added (1.5 µL, to give 30 µg/mL
final), followed by 1 hr incubation with plate shaking. When
streptavidin-donor beads are added to the reaction, they bind
the biotinylated N-terminal APP antibody. When both antibodies
bind with APP1C31, they are in close enough proximity for
excitation at 680 nm to result in the production of 1O2,
interaction with the acceptor bead and emittance at 580 nm
that is then detected using an Envision plate reader (Perkin-
Elmer).
ELISA to Detect APP1C31
The APP1C31 ELISA developed in partnership with Enzo
Life Sciences (ADI-900-227) follows a standard sandwich
ELISA design wherein a monoclonal N-terminal APP-specific
antibody is used to coat the wells of the microtiter plate
(capture antibody) and the anti-APP1C31 cleavage site-specific
polyclonal antibody serves as the detection antibody. An
HRP-conjugated secondary antibody is then added and a
colorimetric signal generated by enzymatic conversion of the
tetramethylbenzidine (TMB) substrate. Protein levels were first
determined using a colorimetric coomassie assay (Coomassie
Plus, Thermo).
Statin Induction of APP1C31 Production
Since APP1C31 is typically produced at very low levels and
below the level of detection in the in vitro systems used here,
it was necessary to induce this caspase cleavage in order to
then knock it down. We previously reported the ability of
statins, including simvastatin and cerivastatin, to stimulate the
caspase cleavage of APP (Descamps et al., 2011). Here, we
utilized this ability to discover APP C-terminal caspase cleavage
inhibitors using CHO-7W cells. Cells were treated with activated
simvastatin at 6 doses ranging from 100 nM to 10 µM, for 7.5
and 24 h, at which time APP1C31 was measured in cell lysates
using the AlphaLISA. Simvastatin was activated by opening the
lactone ring before use in cell culture as previously described
Dong et al. (2009); 8 mg simvastatin was dissolved in 0.2 mL of
100% ethanol (0.019 mM), with subsequent addition of 0.3 mL
of 0.1 N NaOH and the solution was heated at 50◦C for 2 h
and then neutralized with HCl to pH 7.2. The resulting solution
was brought to 1 mL final with distilled water, and aliquots were
stored at−80◦C.
In a separate experiment, CHO-7W cells were treated with:
simvastatin, cerivastatin, and atorvastatin at 1, 5, and 10 µM,
5 µM simvastatin plus 30 µM pan-caspase inhibitor Q-VD-OPh
(QVD, Sigma-Aldrich), and no statins, all for 24 h. APP1C31 was
determined in cell lysates by ELISA.
High-Throughput Screening (HTS) for
Inhibitors of the C-terminal Caspase
Cleavage of APP
For HTS, CHO-7W cells were plated into 384-well Proxiplate
SW plates (Perkin-Elmer) at 4K cells/well/10 µL in the growth
media/conditions described above but also containing 1X
Glutamax, 20 mM HEPES, 1X NEAA and 500 µg/ml G418. The
following day, simvastatin at a final concentration of 10 µM
and test compounds at 30 µM were added to assay plates via
ECHO R© acoustic transfer (Labcyte). The next day, media was
removed from the cells by “Flick and Slam” and centrifuging
upside down. Cells were lysed in 3 µL of AlphaLISA buffer
complemented with protease inhibitors on a plate shaker for
15 min.
The APP1C31 AlphaLISA assay (Figures 2C–E) was run
directly in the plate with the cell lysate as described above
in “AlphaLISA to detect APP1C31.” APP1C31 levels were
measured using the Envision plate reader and data were
normalized to DMSO (100% APP1C31 production) and Q-VD-
OPh (MP Biomedicals) pan-caspase inhibitor at 30 µM (0%);
these controls were present on each plate. In addition, some
compounds of interest were further analyzed in a dose-response
curve to determine IC50 values.
Compound libraries screened and confirmed included: (1) the
US (1040 compounds) and International (240 compounds) Drug
collections (Microsource); (2) the Enzo protease inhibitor library
(60 compounds); and (3) a 903 compound natural products
screen including a 502 compound Enzo natural products library,
a 64 compound EMD inhibitors library, a 97 compound Enzo
autophagy library, and a 240 compound GreenPharma natural
products library.
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Validation of C-terminal APP Cleavage
Inhibitors and Determination of Cell
Viability
A subset of hits from our HTS was validated in a secondary assay.
In addition, since the HTS hit spiperone has been reported to be
a Wnt-signaling pathway inhibitor, we included in our testing
another compound known to affect this pathway, thapsigargin,
along with a spiperone analog 3′-fluorobenzylspiperone
maleate (3′-fluorobenzylspiperone). Thapsigargin also acts
as a sarco/endoplasmic reticulum calcium ATPase (SERCA)
inhibitor. Therefore, another SERCA inhibitor, 2,5-Di-tert-
butylhydroquinone, was also added to the testing. In this
secondary assay, CHO-7W cells were cultured as described above
and plated into 24-well dishes at ∼200K/well. The next day,
cells were treated for 24 h in duplicate with 200 µL fresh media
containing 10 µM cerivastatin (Sigma) to induce APP1C31
production as well as select hits at 3, 10, and 30 µM, although
the more potent thapsigargin was used at 0.033, 0.1, and 0.3 µM,
and 2,5-Di-tert- butylhydroquinone at 1 and 10 µM. These
hits were selected for their potency in primary screen, their
structural features, their known activities, and availability of
compound for additional testing. There were cerivastatin-only
(negative control), + QVD-OPh (positive control), and for
viability, vehicle-only (negative) controls. Cells were harvested
by removing the media to a tube, adding 100 mL trypsin to
detach cells then neutralizing with media. Cell viability (% live)
was determined by trypan blue exclusion using BioRad’s TC-20
cell counter as it was important to ensure that any observed
APP1C31 inhibition was not due to inhibitor toxicity. Cells
were centrifuged at 5000 rpm (2300 × g) for 5 min. Cell pellets
were frozen until use. Forty µL cold RIPA buffer plus complete
protease inhibitors (Roche) was added to each pellet and the
pellets were reconstituted by pipetting up and down, incubating
on ice for 30 min, vortexing, and centrifugation as above. Cell
lysate supernatants were then assayed by APP1C31 ELISA as
described above. For most compounds, multiple/repeat studies
were performed and two wells used for each condition. Statistical
comparison was performed using one-way ANOVA for multiple
comparisons, with a Dunnett post hoc test to compare each
condition to the control. Further dose-response studies were
performed on select compounds.
Ex vivo Hippocampal Slice Cultures
Our lead APP1C31 inhibitors were further tested ex vivo
in I5 mouse organotypic hippocampal slice cultures in pilot
experiments (Supplementary Figure S4). I5 mice express wt
hAPP under the control of the platelet-derived growth factor
promoter (Mucke et al., 2000). I5 mice originally purchased
from Jackson labs (JAX B6.Cg-Tg(PDGFB-APP)5Lms/J) were
bred and maintained in the Buck Institute vivarium facility, and
used under the guidelines of an approved institutional IACUC
protocol. P5–7 day mice were sacrificed using CO2 gas and
cervical dislocation according to established IACUC protocols.
Brains were removed, and under sterile conditions, hippocampi
were dissected out on ice in Hybernate media+ 1:400 Glutamax,
1:100 Pen/Strep and 1:50 B27 supplement (all Life Technologies).
Hippocampi were laid parallel on a tissue chopper (McIlwain) in
a small amount of media and sliced at 400 µm thick. Millicell-CM
6-well cell culture inserts (Millipore, 0.4 µm) were prehydrated
by pipetting 750 µL culture media under each well and placing
in a 35◦C, 5% CO2 incubator for at least 30 min. Culture media:
100 mL MEM-HEPES, 50 mL HBSS, 50 mL HI horse serum, 1 mL
100x Pen/Strep (all Gibco), 1.3 g (6.5 mg/mL) glucose, and 2 mL
200 µM (2 mM) Glutamax, sterile filtered. Approximately equal
portions of sliced hippocampi (4–5 pups/well) were placed onto
inserts in minimal media (as stated above) and cultured for 5 days
before treatment, changing the media under the insert every 2–
3 days. After 5 days, treatment with vehicle (DMSO), cerivastatin
(CS) at 30 µM, or CS plus 30 µM Q-VD-OPh, 10 µM spiperone,
or 30µM 3′-fluorobenzylspiperone for 72 h, with treatment being
replaced under the insert each day. At the end of treatment, tissue
was rinsed gently with PBS and harvested into a tube by gently
scraping off the membrane with a scalpel using ∼100 µL/well
cold RIPA buffer + protease inhibitors. Tissue was sonicated on
ice for ∼5 s at “60” (Sonics Vibra Cell). Tissue sat on ice 30 min,
was vortexed and centrifuged 5 min at 5000 RPM (2300 × g)
before assaying the supernatant. Protein was quantitated for
each sample using Coomassie Plus reagent (Thermo). An AMP’d
Signal Amplification kit (Enzo) was used with the ELISA to detect
APP1C31 in these cultures as the signal was very low.
Protein Concentration and sAPPα Levels
In an additional study (Supplementary Figure S5A),
measurement of the α secretase fragment of full length
(FL) APP – soluble APP alpha (sAPPα) – was performed
using cell media by ELISA (IBL). Furthermore, in two studies
(Supplementary Figures S5B,C), total protein levels in CHO-
7W cell lysates were determined by Coomassie Plus protein assay
(Pierce).
Parallel Artificial Membrane Permeability
Assay (PAMPA)
Several compounds emerged from testing as possible leads. Since
the brain is the target tissue, brain-penetrance is a key feature
of any potential new AD therapeutic. Immobilized artificial
membrane (IAM) chromatography such as PAMPA (parallel
artificial membrane permeability assay) is used to predict a
compound’s passive diffusion through membranes and may
predict blood-brain barrier (BBB) penetrance.
To minimize variability between PAMPA assays for different
compounds, the well-characterized, reliable IAM.PC.DD2
Regis Technologies analytical columns were used. In these
10 cm × 4.6 mm columns, the phospholipid is bonded on
10 µm, 300 Å, spherical aminopropyl silica and end capped with
C10 and C3 amides. It has been reported that, while column
aging depends upon the column used as well as the test analyte,
the intra-batch variability for IAM.PC.DD2 phases was small
(Taillardat-Ertschinger et al., 2002). In addition, Ong et al. (1996)
and others (Yoon et al., 2006; Shin et al., 2009) have shown that
the IAM.PC.DD2 could be used as a rapid screening method for
the prediction for drug absorption. In our hands, this PAMPA
method has shown good correlation with brain-penetrance
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determined in vivo by pharmacokinetic (PK) analysis, and allows
us to prioritize compounds for PK study.
Columns were connected to an Agilent high performance
liquid chromatography system. Compounds (spiperone,
pimozide, and 3′-fluorobenzylspiperone) were prepared at
10 µM in DMSO and diluted to 500 µM in 50:50 water:methanol.
The mobile phase was a mixture of water and methanol and a
gradient was used for the elution of the compounds. The detector
was set at 250 and 280 nm. After a compound was eluted, the
retention time and void volume times were obtained from the
chromatogram.
The IAM capacity factor (KIAM) was calculated using the
equation: KIAM = tr−t0t0 ; where tr is the
retention time of a compounds and t0 is the void volume time
of the column. It has been shown that the membrane permeability
of a drug following passive diffusion is directly proportional to
the KIAM and inversely proportional to the molecular weight of
a compound. To predict the likelihood a compound would be
BBB penetrant, we used the correlation described by Yoon et al.
(2006):
(I) If KIAMMW4 x10
10 > 0.85 the BBB penetration is predicted to be
high
(II) If KIAMMW4 x10
10 < 0.85 the BBB penetration is predicted to be
low
In vivo Pharmacokinetic (PK) Analysis of
Spiperone
As PAMPA is merely a predictive analysis of brain permeability,
a pharmacokinetic (PK) study with spiperone was performed.
Five adult (>3 months of age) male mice (C57B6, Jackson Labs)
were injected subcutaneously (SQ) with 50 µL of spiperone
at 5 mg/mL in 100% DMSO. Another 5 mice were injected
intraperitoneally (IP) at the same dose. One mouse was
euthanized from each dosing route group at 1, 2, 4, 6, and 8 h.
This is done by ketamine/xylazine over- anesthesia followed by
blood collection for plasma isolation by cardiac puncture, and
transcardial perfusion of tissue with saline to remove residual
blood from the brain. Both plasma and brain tissue were sent
to Integrated Analytical Solutions (IAS, Berkeley, CA, USA) for
compound level analysis using an LC-MS-MS method.
The animal testing was carried out in accordance with Public
Health Service Policy on Humane Care and Use of Laboratory
Animals, Assurance # A3196-01 and in the Buck Institute
vivarium that has received AAALAC accreditation.
RESULTS
Specificity of the APP1C31 Antibody
Immunoblot analysis shows that the anti-APP1C31 antibody
is specific for caspase-cleaved APP, and does not react with
full-length APP. As seen in Figure 2A, the band just below
100 kDa expressed after transfection of HEK 293T cells with
pcDNA3-APP1C31, but not for pcDNA3-FL APP is revealed
by the antibody. In Figure 2B, again only APP1C31 induced
by treatment of CHO-7W cells with either staurosporine or
simvastatin produced a band detectable with the antibody; FL
APP present in lysates of untreated CHO-7W cells was not
detected. In both cell types, two non-specific bands appeared (the
lower is a triplet) and while the proteins in these bands have not
been identified, they could be metabolites of APP1C31 or other
non-APP caspase-cleaved proteins with a similar antigenic site. It
is important to note that in both the AlphaLISA and ELISA used
for the screening and validation studies, a second N-terminal
APP-specific antibody is used so that only APP1C31 is detected
and not shorter APP fragments.
Antibody specificity was also confirmed by analysis of
purified MBP (maltose binding protein)-APPC125 (C-terminal
125 amino acids of APP including the β-, α-, γ -, and caspase-
cleavage sites) fusion protein reactivity to anti-APP1C31 as
compared to anti-APP (6E10) by immunoblot where only anti-
APP and not anti-APP1C31 recognized this uncleaved fusion
protein (Supplementary Figure S1A). In addition, overexpressed
APP1C31 and full-length APP695 from HEK 293T cell lysates
were tested by APP1C31 ELISA and showed similar results with
the full-length APP lysate being almost undetectable with less
than 1% cross-reactivity (Supplementary Figure S1B).
Induction of C-terminal APP Cleavage
Using Statins in CHO-7W Cells
As shown in Figure 3A, an initial time- and dose-response study
showed simvastatin induction of APP1C31 was both time and
dose-dependent. Simvastatin increased APP1C31 proportionally
from 1 to 10 µM, and this was seen at 24, but not 7.5 h. Therefore,
a 24-h treatment time was used for further studies. Simvastatin
was then compared to cerivastatin and atorvastatin. Of the statins
tested, cerivastatin was found to be the most effective at inducing
the caspase cleavage of APP (Figure 3B). These results led us to
use cerivastatin in the validation studies.
Induction of cerivastatin-induced APP1C31 production was
also seen by immunoblot. 3′-fluorobenzylspiperone decreased
10 µM CS-induced APP1C31 at 30 µM here (boxed area).
QVD at 30 µM eliminated the cerivastatin-induced APP1C31
increase (Supplementary Figure S2B) and inhibited APP1C31
production in a dose-dependent manner (Supplementary
Figure S2A).
Compound Library Screening for
Inhibitors of the C-terminal Cleavage of
APP
A scatterplot (Figure 4) shows that a total of 91 hits out of
2243 compounds screened (4% hit rate) were found, using a
hit criterion of at least 70% inhibition of APP1C31 production.
The red-filled circle represents the inhibition of APP1C31
by the control pan-caspase inhibitor QVD-OPh, and hits
initially selected for further evaluation that have undergone hit
confirmation are represented by blue-filled circles. Screening was
performed in duplicate and the average coefficient of variation
(CV) across all assays was 17± 4%.
These hits comprised many different categories of compounds
including histone acetyltransferase inhibitors, antibacterials,
antifungals, cathepsin inhibitors, protease inhibitors, kinase
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FIGURE 3 | Statins induce APP1C31 production in a time- and dose-dependent manner. (A) Activated simvastatin treatment of CHO-7W cells for 24 h, but
not 7.5 h, leads to dose-dependent induction of APP1C31 as determined by our APP1C31 AlphaLISA assay; units are relative fluorescent units (RFU). Log−5 is
10 µM, log−7 is 100 nM. (B) Statin treatment of CHO-7W cells for 24 h leads to dose-dependent induction of APP1C31 as determined by the APP1C31 ELISA
developed for these studies. Twenty-four hour simvastatin (Sim) increased APP1C31 at 5 and 10 µM, and cerivastatin (CS) did so at 1, 5, and 10 µM. Atorvastatin
(Ator) was much less effective. Pan-caspase inhibitor Q-VD-OPh prevented 5 µM simvastatin-induced APP1C31 increases. Experiments were performed in
duplicate and statistical analysis performed using ANOVA with Dunnett post hoc analysis to compare all compound effects to the “no statin” control
(∗∗∗∗p < 0.0001).
FIGURE 4 | Scatterplot of HTS hits. Of 2243 compounds tested in HTS
using the AlphaLISA, 91 hits – defined as compounds that inhibited
simvastatin-induced APP1C31 production by at least 70% – were found at a
hit rate of 4%. The pan-caspase inhibitor Q-VD-OPh is represented by the red
circle, and hits that were confirmed and went on to further evaluation are
blue-filled circles (see Supplementary Table S1). Screening was performed
in duplicate and the average coefficient of variation (CV) across all assays was
17 ± 4%.
inhibitors, mTOR inhibitors, natural products, protein synthesis
inhibitors, phosphodiesterase inhibitors, Ca2+ channel blockers,
Ca2+ signaling modulators, GPCR agonists and antagonists, and
anti-inflammatory agents. Identities and APP1C31 inhibition
data for all confirmed hits from our HTS are shown in
Supplementary Table S1. Potential therapeutic hits based on
structure were cherry-picked for further validation and study.
Validation of Inhibitors of the C-terminal
Cleavage of APP
Confirmed screening hits were validated for inhibition of
APP1C31 induction by ELISA using larger format cultures of
CHO-7W cells, and several additional compounds were added
in these secondary assays based on their known mechanisms
of action. Specifically, since the hit spiperone is a known Wnt
signaling inhibitor, another known inhibitor of Wnt signaling
was analyzed as well, thapsigargin. Thapsigargin is also a
SERCA inhibitor, and so another SERCA inhibitor, 2,5-Di-tert-
butylhydroquinone was also analyzed. Dose-response analyses
were performed on hits chosen for their potency and efficacy of
APP1C31 inhibition as well as some for structural features. Some
of these compounds were run in 4- to 8-point dose-response
curves as shown in Figures 5B,C.
Most of these compounds reduced cerivastatin-stimulated
APP1C31 in a dose-responsive manner after 24 h
(Figures 5A–C) with Q-VD-OPh serving as the positive control.
Thapsigargin (Figure 5A, Supplementary Figure S3A) proved
to be a remarkably potent inhibitor of APP1C31 production and
another SERCA inhibitor, 2,5-Di-tert-butylhydroquinone, was
also very effective. HTS hits spiperone, 3′-fluorobenzylspiperone
maleate and pimozide were also potent inhibitors. The IC50
values (µM) of the lead compounds were: spiperone 4.6,
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FIGURE 5 | Validation of select APP1C31 inhibitor hits from screening. (A) Hits revealed by HTS at 30 µM were retested in a larger well format at 3, 10, and
30 µM (unless otherwise specified) using cerivastatin to stimulate APP1C31 production in CHO-7W cells. Q-VD-OPh (red) served as the control for caspase
inhibition and the ELISA was used to determine APP1C31 levels. Thapsigargin and 2,5-Di-tert-butylhydroquinone, while not identified in HTS, were added in
validation studies due to their mechanism of action. N ≥ 2 for CS + QVD, Sp, or 3′F-Sp, and n = 1 – 2 for CS + Pim, Kf, Rap, Tam, SB202, Thap, or 25-di-th.
Statistical analysis was performed using one-way ANOVA for multiple comparisons with Dunnett’s test to compare each treatment to CS at 10 µM alone (∗p ≤0.05,
∗∗p ≤0.005, ∗∗∗p ≤0.001). (B,C) In further validation studies, the dose-response was best for spiperone, 3′-fluorobenzylspiperone and pimozide. The ELISA was
used for determination of APP1C31 in (B), and the AlphaLISA in (C). (D) Increases in percentage of viable cells mirrored APP1C31 reductions in a dose responsive
manner. Untreated cells representing 100% viability are not shown while vehicle (DMSO) treated cells were ∼85% viable. Of the compounds identified in HTS,
3′-fluorobenzylspiperone elicited the greatest increase in cell survival; known SERCA inhibitors thapsigargin and 2,5-Di-tert- butylhydroquinone used at lower doses
had the greatest effect on the rescue of cell viability. N ≥ 2 for veh, CS, QVD, Sp, and 3′F-Sp; n = 1 or 2 for Pim, Kf, Rap, Tam, SB202, Thap, and 25-di- th.
Statistical analysis was performed as described above for (A) to compare compounds in combination with 10 µM CS to CS alone; in addition, CS alone was
compared to the vehicle-only control.
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TABLE 1 | Efficacy of lead APP1C31 inhibitors.
Hit Name Structure MW APP1C31 Inh. (mean %) Cell viability (mean %) IC50
Spiperone 431 41 29 4.6 mM (A)
3′Fluorobenzylspiperone maleate 619 78 54 2.2 mM (A)
Pimozide 461 98 37 3.6 mM (A)
Thapsigargin 651 97 33 (@ 0.1 µM) 0.077 mM (E)
Kaempferol 286 65 19 >10 mM (E)
Rapamycin 914 99 43 >10 mM (E)
Tamoxifen 563 56 14 >10 mM (E)
SB202190 331 58 15 >10 mM (E)
SB216763 371 54 23 >10 mM (E)
QVD-OPh 514 95 38 7.5 µM (E)
Cerivastatin 460 0 15 (@ l0 µM) NA
DMSO 78 0 86 NA
Compounds validated in secondary testing reveal their efficacy to both inhibit APP1C31 and rescue CHO-7W cells from cerivastatin-induced cell death. Induction of
APP1C31 was accomplished with 10 µM cerivastatin and inhibition with 30 µM compound with up to 5 repeats.
pimozide 3.6, 3′-fluorobenzylspiperone maleate 2.2, and
thapsigargin 0.077.
Cerivastatin induction of APP1C31 and inhibition by Q-VD-
OPh and 3′-fluorobenzylspiperone in a dose-dependent manner
was also demonstrated by APP1C31 immunoblots from CHO-
7W cell lysates (Supplementary Figure S2).
Since APP1C31 is generated by caspase cleavage and we
found some MEK inhibitors in our HTS, select caspase and
MEK inhibitors were also tested for inhibition of cerivastatin-
induced APP1C31 in CHO-7W cells for 24 h using dose-
response curves determined by AlphaLISA (Supplementary
Figure S3B). They included Caspase 6 Inhibitor I and II, Caspase
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FIGURE 6 | Parallel artificial membrane permeability assay (PAMPA) and PK analysis. (A) PAMPA analysis suggests that spiperone would have the highest
likelihood of being brain-penetrant. (B) PK analysis indicated that after IP injection at 10 mg/kg, brain levels peaked (Cmax) at ∼205 ng/g at 1 h (n = 1 mouse per
time point).
Inhibitor X (inhibits caspases 3, 7, and 8), AZ10417808 (inhibits
caspase 3) and Ivachtin (inhibits caspase 3). Although none of
these caspase inhibitors were found to be very effective here,
Caspase Inhibitor X (potency for various caspases: caspase 3
IC50 4.3 µM; caspase 7 IC50 6.2 µM; caspase 8 IC50 2.7 µM)
and Caspase 6 Inhibitor I at the highest concentration tested
(30 µM) were somewhat effective. The broad-spectrum pan-
caspase inhibitor Q-VD-OPh served as the positive control.
The MEK1/2 (MAPK/ERK kinases) inhibitor U0126 reduced
APP1C31 ∼25% from 10 to 50 µM while the inactive
isomer U0124 was ineffective. The MEK inhibitor SL327 was
ineffective.
Lead APP1C31 inhibitors were also tested in P5–7 day
I5 wt mouse ex vivo organotypic hippocampal slice cultures
(Supplementary Figure S4). These pilot studies were
performed for lead compounds and it should be noted
that the APP1C31 signal was found to be low. Results
within each experiment were protein normalized and are
represented as % of cerivastatin control, which was set at
100% for each experiment, and thus there are no error bars
for that treatment. Spiperone at 10 µM inhibited APP1C31
production by ∼14% while 3′-fluorobenzylspiperone maleate
at 30 µM inhibited it by ∼82%. Preliminary results suggest
that these compounds are also efficacious ex vivo with,
and some without, cerivastatin induction. Interestingly,
pilot studies in primary I5 neuronal cultures treated with
cerivastatin did not induce APP1C31, additional investigation
with neuronal cultures were not done as we found that
the APP1C31 could be induced by cerivastatin in slice
cultures.
Rescue of Cell Viability by Validated Hits
Cell viability was measured together with APP1C31 since
induction of APP1C31 production (here stimulated by
cerivastatin) increases cell death. It was also important to
ensure that any observed APP1C31 reduction was not
due to compound toxicity. As seen in Figure 5D, increases
in cell viability typically mirrored decreases in APP1C31,
confirming the toxic effect of the caspase cleavage of APP.
Among hits from HTS, spiperone, pimozide, and rapamycin
showed the greatest cell survival rescue effects at 30 µM.
Of these, two compounds that were added to secondary
screening due to their known mechanism(s) of action –
thapsigargin and 2,5-Di- tert-butylhydroquinone – elicited
the highest cell survival among compounds tested at the low
concentrations. Complete APP1C31 inhibition and viability
data for all confirmed hits are shown in Table 1. Cell viability
for hits tested represents rescue if greater than the level of
cerivastatin treatment alone. DMSO represents maximal
viability.
Effects on Protein and sAPPα Levels
As shown in Supplementary Figure S5A, treatment of CHO-
7W with QVD, spiperone and 3′fluorobenzylspiperone increased
sAPPα in the presence 10 µM cerivastatin, did not significantly
affect sAPPα indicating that these compounds do not affect
APP expression. Furthermore, QVD alone at 30 µM and
spiperone alone at 10 µM did not lower protein concentration
in CHO-7W lysates as compared to vehicle as shown in
Supplementary Figure S5B. In addition, and S5C QVD,
spiperone and 3′fluorobenzylspiperone alone at 30, 10, and
10 µM, respectively, increased total protein concentration
in the presence of 10 µM cerivastatin (Supplementary
Figure S5C).
PAMPA and PK
As shown in Figure 6A, of the three compounds tested in
PAMPA, spiperone had the lowest tr and KIAM and the
highest KIAMMW4 x10
10, and thus was predicted to be more brain-
penetrant than pimozide or 3′-fluorobenzylspiperone maleate.
This was not unexpected as spiperone also has the lowest
MW of the three compounds. Pharmacokinetic analysis revealed
spiperone did indeed enter the brain, peaking at 1 h for both
the subcutaneous and intraperitoneal routes at ∼70 ng/g and
∼205 ng/g, respectively (Figure 6B). Plasma levels were higher
at all time points and by both routes, with a brain:plasma ratio
of∼0.5.
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DISCUSSION
Our laboratory and others (Lu et al., 2000; Banwait et al., 2008)
have shown that the intracellular caspase cleavage of APP
resulting in the production of APP-C31 is a destructive
physiological process involved in AD. It has been shown
that overexpression of APP-C31 in cortical neurons results in
apoptotic cell death (McPhie et al., 2001), and that in a murine
model of AD, prevention of APP-C31 generation by mutation
of the D664 (of APP695) cleavage site reduced synaptic loss
and improved synaptic transmission and spatial memory. Thus,
identification of inhibitors of cleavage at this site would be
instrumental in understanding the role of this cleavage in the
disease process and represents a novel and potentially important
new approach to therapeutic development in AD.
Statin-induced APP1C31 (and thus APP-C31) increases
could have therapeutic implications, especially for those at high
risk for AD due to the expression of apolipoprotein E4 (ApoE4).
Individuals expressing ApoE4 are at greater risk for both AD
(Bertram et al., 2007; Mahley et al., 2007; Waring and Rosenberg,
2008) and cardiovascular disease (Mahley, 1988, 2016) and may
receive statins as part of a program to lower their risk of the latter.
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors used to inhibit cholesterol biosynthesis
and in this way protect against vascular disease. While the exact
mechanism is not known, memory loss associated with the use
of statins has been reported (Strom et al., 2015) although there
is concern around selection or detection bias in such reports.
The risk of statin- induced memory impairment, however, should
be considered for individuals at risk for AD. Cerivastatin was
voluntarily withdrawn from the worldwide market in 2001
due to reports of fatal rhabdomyolysis (Bruno-Joyce et al.,
2001). However, simvastatin, another lipophilic and highly brain-
permeable statin effective in stimulating APP1C31 production
(albeit less so than cerivastatin), is still on the pharmaceutical
market. Atorvastatin, also seen to increase APP1C31 in our
earlier studies (Descamps et al., 2011) as well as these studies, has
a much weaker effect than do cerivastatin and simvastatin, and is
hydrophilic with relatively low brain-permeability.
In contrast to what might be considered a risk associated with
statin use, statins have been considered potential therapeutics
for several CNS disorders, including ischemic stroke, AD,
and multiple sclerosis (Ciurleo et al., 2014), as well as for
cancer treatment (Werner et al., 2004; Cafforio et al., 2005;
Minichsdorfer and Hohenegger, 2009). The effect of statins on
the CNS includes effects that may be of benefit in AD prevention
such as decreased Aβ production, increased Aβ clearance, and
decreased reactive oxygen species (ROS) production as well as
neuroinflammation. However, the effects of statins appear to be
of less utility once AD is present (McFarland et al., 2014). Overall,
there is thought to be a role of statins in reducing cholesterol in
AD (Sun et al., 2015) but even this is not without controversy
(Wood et al., 2014). As with all potential therapeutic approaches,
the use of statins effectively may rest on appropriate diagnosis,
timing, and individual patient cholesterol status.
Statins are also known to have anti-proliferative effects in
certain tumor cell types (Baulch-Brown et al., 2007; Relja
et al., 2010) and this effect is attributed in part to reduction
of the isoprenylation of proteins involved in cell signal
transduction such as Ras and RhoA (Cafforio et al., 2005).
Cafforio et al. (2005) and others (Werner et al., 2004) have
demonstrated that many statins, especially lipophilic ones such
as cerivastatin, exert cytotoxic effects on tumor cells by directly
promoting apoptosis through the intrinsic pathway involving
mitochondria as opposed to the extrinsic death receptor pathway.
A reduction in mitochondrial membrane potential and the
cytosolic release of a second mitochondria-derived activator of
caspases (Smac/DIABLO) was observed. They determined that
this apoptotic pathway was caspase-dependent since caspases
9, 3 and 8 were activated; cerivastatin induced the maximum
activation. They also showed that a caspase 9 inhibitor
dramatically reduced apoptosis in MCC-2 cancer cells whereas
a caspase 8 inhibitor did not. They therefore speculate that
caspase 9 is the likely initiator whereas caspase 8 is subsequently
transformed by caspase 3 into its active form. Caspase 8 activation
by longer statin incubation times was confirmed in melanoma
cells (Minichsdorfer and Hohenegger, 2009) although Werner
et al. (2004) found that extrinsic pathways via death receptors
through caspase 8 and calpain activation were not triggered
by simvastatin and that deprivation of cholesterol precursors is
essential for statin-induced apoptosis. Caspase 2 gene expression
has been shown to be induced upon treatment with lovastatin
in thyroid cancer cells (Zhong et al., 2003), and the caspase
7 gene has been identified as a novel statin-responsive gene
(Gibot et al., 2009). In C6 glioma cells, statin (mevastatin and
simvastatin) treatment led to the suppression of cell proliferation
and induction of apoptosis (Yanae et al., 2011) where they
measured an increase in caspase-3 activity through inhibition of
geranylgeranyl diphosphate (GGPP) biosynthesis and found that
these statins inhibit the activation of phosphorylated ERK 1/2
and Akt. Therefore, it is not surprising that our hit compounds
not only inhibited the production of APP1C31 and thus
cytotoxic APP-C31, but they also rescued the CHO-7W cells
from cerivastatin-induced cell death, over-riding the apparent
statin-induced caspase activation.
As mentioned, analysis of the hits from our primary
and secondary assays yielded many categories of potential
targets such as histone acetyltransferase inhibitors, antibacterials,
antifungals, cathepsin inhibitors, protease inhibitors, kinase
inhibitors, mTOR inhibitors, natural products, protein synthesis
inhibitors, phosphodiesterase inhibitors, Ca2+ channel blockers,
Ca2+ signaling modulators, GPCR agonists and antagonists,
and anti-inflammatory agents. While there may be a network
of targets involved in this C-terminal APP cleavage, further
work is needed to demonstrate their involvement such as
knockout and overexpression experiments as well as validation
using commercially available compounds or analogs directed
against the specific targets. One could posit that the APP1C31
reduction induced by the key compounds identified in this work
could be due, in part, to a decrease in protein expression, or
specifically expression of FL APP and this could lead to less
FL APP interaction and reduced cell death (Park et al., 2009).
However, our data on both total protein concentration and
sAPPα levels from cells treated with these compounds alone
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or in combination with cerivastatin suggest that protein/APP
expression lowering by these lead compounds is not a likely
factor in their APP1C31 reductions (Supplementary Figure S5).
Furthermore, our key inhibitors reverse the cerivastatin-induced
decrease in cell viability, and this rescue mirrored the reduction
in APP1C31 levels (Figures 5A,D). Nonetheless, in the future
as these lead candidates or their analogs progress toward
preclinical development additional mechanistic analysis will
include determination of their effect on APP expression at both
the RNA and protein levels.
At least two of our lead APP1C31 inhibitors, spiperone
and thapsigargin, are known to affect calcium mobilization
induced by a Wnt ligand and to inhibit Wnt pathway activation
(Lu and Carson, 2009; Thrasivoulou et al., 2013). The Wnt
signaling pathway plays important roles in the regulation of cell
proliferation, differentiation and apoptosis (Li et al., 2006). These
findings suggest that regulation of intracellular calcium levels and
thus the Wnt pathway could be playing a role in APP1C31 and
APP-C31 production.
It is not, however, a given that Wnt-signaling should be
inhibited in AD. In fact, it may be contraindicated, at least
in advanced AD. Inestrosa et al. (2012) reported a correlation
between loss of Wnt signaling and Aβ toxicity as well as tau
hyperphosphorylation, and that conversely, upregulation of the
Wnt pathway prevented toxicity. In addition, Liu et al. indicated
dysfunctional Wnt/β-catenin signaling affects BBB function and
contributes to neurodegeneration in AD (Liu et al., 2014).
Since more APP1C31 is found in early AD Braak staging, and
not in late AD (Banwait et al., 2008), it may occur at a time when
Wnt signaling compensation is underway in response to early
dysfunction. In fact, it may be this compensation that leads, in
part, to increased APP1C31/APP-C31 production in early AD.
Therefore, Wnt signaling inhibition may be appropriate at this
time, but not later when Wnt signaling is downregulated. Further
evidence that Wnt signaling should be supported in advanced AD
comes from an extensive study of post-mortem AD brain wherein
a wide range of alterations in components of the Wnt pathway
was seen, likely resulting in dysfunction of the canonical Wnt
pathway, particularly in the hippocampus and entorhinal cortex,
two regions of brain severely compromised in AD (Riise et al.,
2015). Not unexpectedly then, activation of the Wnt signaling
pathway was shown to improve cognition in an AD mouse model
(Skaper, 2014).
Our lead compound spiperone is an antipsychotic that acts
as a potent dopamine D2, serotonin 5HT1A and 5HT2A
antagonist and a sigma receptor ligand. The second lead
compound, 3′-fluorobenzylspiperone, is a selective D2 ligand
and also a strong APP C-terminal cleavage inhibitor. Anti-
psychotics are frequently used in AD patients, and long-
term use of antipsychotics has not been shown to either
improve or worsen AD (Lopez et al., 2013), although it
should be noted that spiperone itself is not commonly
used. Spiperone is the only antipsychotic that shows an
inhibitory effect on Wnt signaling (Lu and Carson, 2009);
the other antipsychotic identified as a hit here, pimozide,
also strongly inhibits APP1C31 but does not inhibit Wnt
signaling.
It is unclear whether these inhibitory compounds are acting
directly or indirectly to inhibit the intracellular caspase cleavage
of APP and what signaling mechanisms are involved, but it could
be speculated that intracellular Ca2+ perturbations/flux could
very well be involved since the SERCA inhibitor thapsigargin
consistently produced such a dramatic effect (IC50 = 77 nM)
including viability rescue. Our data also demonstrate that 2,5-
Di-tert-butylhydroquinone – also a SERCA inhibitor – strongly
inhibits APP1C31 production. It is interesting to note that
both have been reported to modulate intracellular calcium (Sakai
and Teshima, 2001). Modulation of calcium levels may have a
therapeutic role in AD since dysregulation of neuronal calcium
levels in AD is well known and part of the ‘calcium hypothesis’
of AD (Khachaturian, 1987; Mattson, 1992, 1994). Dysregulation
of intracellular Ca2+ in neurons and other cell types in the
brain is strongly associated with chronic inflammation and AD
(Tan et al., 2012; Brawek and Garaschuk, 2014) and calcium
channel blockers may play a role in AD therapy (Tan et al., 2012).
SERCA inhibition, however, operates at the level of the ER, and
calcium channel blockers at the plasma membrane, although both
have effects on cytoplasmic Ca2+. SERCA inhibitors and calcium
channel blockers may have opposing effects, or SERCA inhibition
achieves the desired effect in vitro and only under conditions of
statin treatment, and may not be a desired mechanism in vivo.
Further studies are needed to elucidate the role of each.
The chemical-genetics approach we used in this work allowed
us to identify inhibitors of the intracellular caspase cleavage
of APP and potential targets that warrant further evaluation
for development of new AD therapeutics. We plan to evaluate
the lead candidates identified in this discovery effort, such as
spiperone, 3′-fluorobenzylspiperone and pimozide, in more than
one murine model of AD. Here, compounds were identified
and validated in cells and tissues expressing wt hAPP. We also
plan to test our compounds in a mouse model carrying familial
hAPP mutations. Based on these efficacy results, additional lead
optimization efforts to identify effective APP1C31 inhibitors
would be conducted. Furthermore, we plan to perform HTS
on the UCLA Molecular Screening Core compound library to
identify additional inhibitors of APP1C31 production.
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FIGURE S1 | The APP1C31 polyclonal antibody and ELISA are specific for
APP1C31 rather than full-length APP. (A) Purified MBP (Maltose Binding
Protein)-APPC125 (C-terminal 125 amino acids of APP including the β-, α-, γ -
and caspase cleavage sites) fusion protein was the antigen electrophoresed, and
anti-APP (6E10) or anti-APP1C31 were the antibodies used to probe the
immunoblot membranes. (B) For APP1C31 ELISA validation, increasing doses of
lysates from pcDNA3-APP1C31-transfected or pcDNA3-APP695-transfected
HEK 293T cells were compared.
FIGURE S2 | Cerivastatin induction of APP1C31 and inhibition by
3′-fluorobenzylspiperone maleate and Q-VD-OPh as seen by immunoblot.
(A) CHO-7W cells were treated with 10 µM cerivastatin (CS) along with varying
concentrations of Q-VD-OPh (QVD) for 24 h. Cell lysates were prepared and
immunoprecipitated with anti-APP (6E10) overnight at 4◦C and then incubation
with Protein A/G beads (Santa Cruz Biotech). The resulting pellets were incubated,
electrophoresed using Nupage 4–12% Bis-Tris gels (Life Technologies) and the
0.2 µm PVDF membrane probed with anti-APP1C31. (B) CHO-7W cells were
treated with increasing concentrations of CS or 10 µM CS together with increasing
concentrations of 3′-fluorobenzylspiperone maleate (3′-F-Sp) or 30 µM QVD for
24 h. Lysates were prepared and membranes probed with anti-APP1C31.
FIGURE S3 | Dose-response curves of APP1C31 inhibition by thapsigargin
and select caspase and MEK inhibitors (A) CHO-7W cells were treated with
10 µM cerivastatin plus increasing doses of thapsigargin for 24 h. Lysates were
prepared and APP1C31 determined by ELISA. (B) CHO-7W cells were treated
with 10 µM cerivastatin plus increasing doses of caspase and MEK inhibitors for
24 h. Lysates were prepared and APP1C31 determined by AlphaLISA.
FIGURE S4 | Pilot testing of lead APP1C31 inhibitors in ex vivo
organotypic hippocampal slice cultures. Hippocampal tissue from P5–7 day
I5 wildtype APP mice was isolated, cultured and treated with 30 µM
cerivastatin ± 30 µM Q-VD-OPh (QVD), 10 µM spiperone (Sp), or 30 µM
3′-fluorobenzylspiperone maleate (3′F-Sp) for 72 h. Tissue was harvested and
lysates analyzed for APP1C31 by ELISA. Lysates were protein normalized and
expressed as a % of control.
FIGURE S5 | Effect of lead compounds on protein concentration and
sAPPα. (A) QVD, spiperone (Sp), and 3′fluorobenzylspiperone (3′F-Sp) at 10, 30,
and 30 mM, respectively, in combination with 10 µM cerivastatin (CS) increased
sAPPα determined in media from CHO-7W cultures treated for 24 h as compared
to CS alone (n = 2). (B) Total protein from lysates of CHO-7W cells treated with
either 30 µM QVD or 10 µM Sp alone for 24 h was similar to the vehicle control
(n = 1). (C) Total protein from CHO-7W lysates treated with 10 µM CS alone or in
combination with QVD, Sp, or 3′F-Sp at the concentrations shown increased
(n = 1). Statistical analysis was performed using one-way ANOVA and Dunnett
post-test for comparison to the 10 µM CS control
(∗∗p < 0.001, ∗∗∗p < 0.0001).
TABLE S1 | Compounds identified as ‘Hits’ in HTS and confirmed.
Confirmed hits from the HTS are listed here along with their % APP1C31
response.
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